Sprint Bioscience (Sweden) Performance

SPRINT Stock  SEK 2.18  0.04  1.87%   
Sprint Bioscience holds a performance score of 13 on a scale of zero to a hundred. The entity has a beta of 0.83, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, Sprint Bioscience's returns are expected to increase less than the market. However, during the bear market, the loss of holding Sprint Bioscience is expected to be smaller as well. Use Sprint Bioscience potential upside, as well as the relationship between the kurtosis and day typical price , to analyze future returns on Sprint Bioscience.

Risk-Adjusted Performance

Good

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Sprint Bioscience AB are ranked lower than 13 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, Sprint Bioscience sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
Begin Period Cash Flow27.1 M
Total Cashflows From Investing Activities-2.7 M
  

Sprint Bioscience Relative Risk vs. Return Landscape

If you would invest  67.00  in Sprint Bioscience AB on November 21, 2025 and sell it today you would earn a total of  151.00  from holding Sprint Bioscience AB or generate 225.37% return on investment over 90 days. Sprint Bioscience AB is generating 2.7687% of daily returns and assumes 15.7033% volatility on return distribution over the 90 days horizon. Simply put, majority of traded equity instruments are less risky than Sprint on the basis of their historical return distribution, and most equity instruments are likely to generate higher returns than the company over the next 90 trading days.
  Expected Return   
       Risk  
Assuming the 90 days trading horizon Sprint Bioscience is expected to generate 21.06 times more return on investment than the market. However, the company is 21.06 times more volatile than its market benchmark. It trades about 0.18 of its potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.15 per unit of risk.

Sprint Bioscience Target Price Odds to finish over Current Price

The tendency of Sprint Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 2.18 90 days 2.18 
roughly 2.75
Based on a normal probability distribution, the odds of Sprint Bioscience to move above the current price in 90 days from now is roughly 2.75 (This Sprint Bioscience AB probability density function shows the probability of Sprint Stock to fall within a particular range of prices over 90 days) .
Assuming the 90 days trading horizon Sprint Bioscience has a beta of 0.83. This usually implies as returns on the market go up, Sprint Bioscience average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Sprint Bioscience AB will be expected to be much smaller as well. In addition to that Sprint Bioscience AB has an alpha of 2.4495, implying that it can generate a 2.45 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta).
   Sprint Bioscience Price Density   
       Price  

Predictive Modules for Sprint Bioscience

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Sprint Bioscience. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Hype
Prediction
LowEstimatedHigh
0.112.1417.98
Details
Intrinsic
Valuation
LowRealHigh
0.112.2918.13
Details
Naive
Forecast
LowNextHigh
0.052.4318.27
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
-2.391.946.27
Details

Sprint Bioscience Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Sprint Bioscience is not an exception. The market had few large corrections towards the Sprint Bioscience's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Sprint Bioscience AB, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Sprint Bioscience within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
2.45
β
Beta against Dow Jones0.83
σ
Overall volatility
0.37
Ir
Information ratio 0.16

Sprint Bioscience Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Sprint Bioscience for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Sprint Bioscience can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Sprint Bioscience is way too risky over 90 days horizon
Sprint Bioscience appears to be risky and price may revert if volatility continues
The company reported the revenue of 35.11 M. Net Loss for the year was (25.08 M) with profit before overhead, payroll, taxes, and interest of 24.59 M.
Sprint Bioscience AB has accumulated about 13.82 M in cash with (40.12 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.19.
Roughly 35.0% of the company outstanding shares are owned by corporate insiders

Sprint Bioscience Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Sprint Stock often depends not only on the future outlook of the current and potential Sprint Bioscience's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Sprint Bioscience's indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding107.5 M
Cash And Short Term Investments70.6 M

Sprint Bioscience Fundamentals Growth

Sprint Stock prices reflect investors' perceptions of the future prospects and financial health of Sprint Bioscience, and Sprint Bioscience fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Sprint Stock performance.

About Sprint Bioscience Performance

By analyzing Sprint Bioscience's fundamental ratios, stakeholders can gain valuable insights into Sprint Bioscience's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Sprint Bioscience has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Sprint Bioscience has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Sprint Bioscience AB develops pharmaceutical products in the areas of cancer and metabolism. Sprint Bioscience AB was founded in 2009 and is based in Huddinge, Sweden. Sprint Bioscience operates under Pharmaceuticals And Biosciences classification in Sweden and is traded on Stockholm Stock Exchange.

Things to note about Sprint Bioscience performance evaluation

Checking the ongoing alerts about Sprint Bioscience for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Sprint Bioscience help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Sprint Bioscience is way too risky over 90 days horizon
Sprint Bioscience appears to be risky and price may revert if volatility continues
The company reported the revenue of 35.11 M. Net Loss for the year was (25.08 M) with profit before overhead, payroll, taxes, and interest of 24.59 M.
Sprint Bioscience AB has accumulated about 13.82 M in cash with (40.12 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.19.
Roughly 35.0% of the company outstanding shares are owned by corporate insiders
Evaluating Sprint Bioscience's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Sprint Bioscience's stock performance include:
  • Analyzing Sprint Bioscience's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Sprint Bioscience's stock is overvalued or undervalued compared to its peers.
  • Examining Sprint Bioscience's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Sprint Bioscience's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Sprint Bioscience's management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Sprint Bioscience's stock. These opinions can provide insight into Sprint Bioscience's potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Sprint Bioscience's stock performance is not an exact science, and many factors can impact Sprint Bioscience's stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Complementary Tools for Sprint Stock analysis

When running Sprint Bioscience's price analysis, check to measure Sprint Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sprint Bioscience is operating at the current time. Most of Sprint Bioscience's value examination focuses on studying past and present price action to predict the probability of Sprint Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sprint Bioscience's price. Additionally, you may evaluate how the addition of Sprint Bioscience to your portfolios can decrease your overall portfolio volatility.
Global Correlations
Find global opportunities by holding instruments from different markets
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios